ライフサイエンスコーパス: cancer-testis antigen

1 d in various human tumors, defining SSX as a cancer/testis antigen.

2 TRAG-3 has been reported to be a cancer/testis antigen.

3 demethylation of endogenous retroviruses and cancer testis antigens.

4 topes predominantly from differentiation and cancer-testis antigens.

5 mmon regulatory mechanisms for this group of cancer-testis antigens.

6 and in some cases shared differentiation or cancer-testis antigens.

7 t SPAN-Xb is a novel member of the family of cancer/testis antigens aberrantly expressed by, and capa

8 er 1, is characterized by high expression of cancer testis antigen and proliferation-associated genes

9 ssed in the medulloblastoma include PRAME, a cancer-testis antigen and potential targets for immunoth

10 action between melanoma antigen-11 (MAGE-11) cancer-testis antigen and the major HIF-alpha hydroxylat

11 -PCR analysis demonstrates that SPAN-Xb is a cancer/testis antigen and shows a restricted normal tiss

12 ecific traits included expression of several cancer/testis antigens and the c-kit proto-oncogene thro

13 tissue differentiation antigens), NY-ESO-1 (cancer/testis antigen) and survivin (inhibitor of apopto

14 of choice include mutant sequences, selected cancer testis antigens, and viral antigens.

15 In contrast to the fact that many cancer/testis antigens are poorly immunogenic, the TAG-d

16 sine residue at position 124 of the NY-ESO-1 cancer/testis antigen as the acceptor site for the forma

17 st that CSAGE belongs to the growing list of cancer/testis antigens as well.

18 Cancer/testis antigen cancer-associated gene (CAGE) is k

19 The cancer testis antigen (CTA) preferentially expressed ant

20 The cancer testis antigen (CTA) preferentially expressed ant

21 Its product is a cancer testis antigen (CTA), and it is often expressed i

22 Cancer-testis antigens (CTA), such as NY-ESO-1, MAGE-A1,

23 Here, we describe the de novo induction of a cancer/testis antigen (CTA) for immunotherapy of tumors

24 Many MGCA are also expressed as cancer/testis antigens (CTA) in human cancers, but the t

25 es in the tumor lines, 6 were members of the cancer/testis antigen (CTAG) gene group including 5 MAGE

26 Cancer testis antigens (CTAgs) are expressed by the majo

27 Cancer testis antigens (CTAs) represented a poorly chara

28 Cancer-testis antigens (CTAs) are normally expressed in

29 biased to the testis, collectively known as cancer-testis antigens (CTAs).

30 The cancer/testis antigens (CTAs) are an important group of

31 PRAME belongs to a group of cancer/testis antigens (CTAs) that are characterized by

32 -expressed in soma-derived human cancers as "cancer/testis antigens" (CTAs), and piRNA (PIWI-interact

33 al transition; (c) coordinated activation of cancer/testis antigens; (d) coordinated down-regulation

34 NY-ESO-1 is a "cancer-testis" antigen expressed in epithelial ovarian c

35 It also enhances immunity to NY-ESO-1, a cancer/testis antigen expressed in a subset of patients

36 responses than women, likely due to gonadal cancer-testis-antigen expression.

37 Analysis of cancer/testis antigen expression and CD8 T-cell abundanc

38 ssion of MAGEA2, and related members of this cancer-testis antigen family, is upregulated in tamoxife

39 POTE is a new primate-specific member of the cancer-testis antigen family.

40 BORIS, like other members of the 'cancer/testis antigen' family, is normally expressed in

41 NY-ESO-1 is a "cancer-testis" antigen frequently expressed in epithelia

42 AG-1, TAG-2a, TAG-2b, and TAG-2c) of a novel cancer/testis antigen gene have been identified and are

43 rough this analysis, we show that a class of cancer testis antigen genes undergoes CpG island hypomet

44 ubtypes and two of the AD subtypes expressed cancer testis antigen genes, whereas three AD subtypes e

45 Unlike most cancer/testis antigen genes which are located on the X c

46 nduce helper T cells against melanocytic and cancer-testis antigens, has been shown to induce specifi

47 ed immunohistochemical analysis for TILs and cancer testis antigens in 117 cases of epithelial ovaria

48 ntigen-specific T-cell responses against six cancer-testis antigens in peripheral blood lymphocytes f

49 gene, located on chromosome Xq28, encodes a cancer/testis antigen in human.

50 his is the first report on the expression of cancer/testis antigens in chondrosarcoma.

51 cted SPAG5 and TSSK6 as putative immunogenic cancer/testis antigens in multiple cancers.

52 state-associated gene 4 (PAGE4), an X-linked cancer/testis antigen, is highly up-regulated in the epi

53 suggested by identifying reactivation of the cancer-testis antigens MAGE and RAGE in ACHN cells after

54 Three of the 13 antigens were cancer/testis antigens (MAGEA3, SSX2, and NY-ESO-1), whi

55 ften include CD8(+) T cells specific for the cancer testis antigen NY-ESO-1.

56 The cancer-testis antigen NY-ESO-1 is one of the most promis

57 mor shrinkage with antibody responses to the cancer-testis antigen NY-ESO-1, changes in peripheral-bl

58 a naturally processed peptide shared by the cancer-testis antigens NY-ESO-1 and LAGE-1.

59 Salmonella typhimurium engineered to deliver cancer/testis antigen NY-ESO-1 through type III secretio

60 We studied cross-presentation of the cancer/testis antigen, NY-ESO-1, and the melanoma differ

61 815, which expresses the naturally occurring cancer/testis antigen P1A, or the corresponding tumor P1

62 We show here that the cancer/testis antigen PASD1 fulfills this role to suppre

63 y expressed antigen in melanoma (PRAME) is a cancer-testis antigen that is expressed in many cancers

64 sts of more than 60 genes, many of which are cancer-testis antigens that are highly expressed in canc

65 breakpoint (SSX) proteins comprise a set of cancer-testis antigens that are upregulated in MHC class

66 ESO-1 thus represents the first example of a cancer/testis antigen that is a also damage-associated m

67 ene 4 (PAGE4) is an intrinsically disordered cancer/testis antigen that is up-regulated in the fetal

68 een subpopulations of TILs and expression of cancer testis antigens was investigated, as well as betw

69 ively strong immunogenicity of a non-mutated cancer/testis antigen, we found that NY-ESO-1 forms poly

70 The NY-ESO-1 cancer/testis antigen, which is expressed in 80% of pati

71 l 94 amino acids of L552S are identical to a cancer testis antigen, XAGE-1, found in Ewing's sarcoma.